Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis

Cancer Treatment Reviews

Volumn 39, Issue 4, 2013, Pages 340-349

  Terasawa, Teruhiko ^a,b,c   Trikalinos, Nikolaos A ^d   Djulbegovic, Benjamin ^e,f   Trikalinos, Thomas A ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TUFTS MEDICAL CENTER   (United States)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CLL; Meta analysis; Treatment

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; MELPHALAN; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875521993     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.05.007     Document Type: Review

References (60)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Morton L.M., Wang S.S., Devesa S.S., Hartge P., Weisenburger D.D., Linet M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
3. Brenner H., Gondos A., Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 2008, 111:4916-4921.
4. Dighiero G., Hamblin T.J. Chronic lymphocytic leukaemia. Lancet 2008, 371:1017-1029.
5. Shanafelt T.D., Kay N.E. Comprehensive management of the CLL patient: a holistic approach. Hematology (Am Soc Hematol Educ Program) 2007, 2007:324-331.
6. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999, 91:861-868. CLL Trialists' Collaborative Group.
7. Steurer M., Pall G., Richards S., Schwarzer G., Bohlius J., Greil R. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev 2006, 32:377-389.
8. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica 2012, 97:428-436. CLL Trialists' Collaborative Group.
9. National Comprehensive Cancer Network. Non-Hodgkin's Lymphomas, Version 2.2012. NCCN Clinical Practice Guidelines in Oncology. 2012.
10. Eichhorst B., Dreyling M., Robak T., Montserrat E., Hallek M. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl. 6):vi50-vi54.
11. Hallek M., Pflug N. Chronic lymphocytic leukemia. Ann Oncol 2010, 21(Suppl. 7):vii154-vii164.
12. Gribben J.G., O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011, 29:544-550.
13. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900.
14. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324.
15. Robinson K.A., Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002, 31:150-153.
16. Steurer M., Pall G., Richards S., Schwarzer G., Bohlius J., Greil R. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2006, 3:CD004270.
17. Kimby E., Brandt L., Nygren P., Glimelius B. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncol 2001, 40:224-230.
18. Zhu Q., Tan D.C., Samuel M., Chan E.S., Linn Y.C. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma 2004, 45:2239-2245.
19. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
20. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
21. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. 2008.
22. Dersimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
23. Bradburn M.J., Deeks J.J., Berlin J.A., Russell L.A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 26:53-77.
24. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
25. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
26. Lu G., Ades A.E. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006, 101:447-459.
27. Salanti G., Ades A.E., Ioannidis J.P. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011, 64:163-171.
28. Montserrat E., Alcala A., Alonso C., Besalduch J., Moraleda J.M., Garcia-Conde J., et al. A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. Nouv Rev Fr Hematol 1988, 30:429-432.
29. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990, 75:1422-1425. French Cooperative Group on Chronic Lymphocytic L.
30. Montserrat E., Fontanilles M., Estape J. Treatment of chronic lymphocytic leukemia: a preliminary report of Spanish (PETHEMA) trials. Leuk Lymphoma 1991, 5:89-91.
31. Kimby E., Mellstedt H. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type: a randomized trial. Leuk Lymphoma 1991, 5:93-96.
32. Catovsky D., Richards S., Fooks J., Hamblin T.J. CLL trials in the United Kingdom: the Medical Research Council CLL Trials 1, 2 and 3. Leuk Lymphoma 1991, 5:105-111.
33. Raphael B., Andersen J.W., Silber R., Oken M., Moore D., Bennett J., et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 1991, 9:770-776.
34. Hansen M.M., Andersen E., Birgens H., Christensen B.E., Christensen T.G., Geisler C., et al. CHOP versus chlorambucil + prednisolone in chronic lymphocytic leukemia. Leuk Lymphoma 1991, 5:97-100.
35. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia. Leuk Lymphoma 1994, 13:449-456. French Cooperative Group on Chronic Lymphocytic L.
36. Jaksic B., Brugiatelli M., Krc I., Losonczi H., Holowiecki J., Planinc-Peraica A., et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997, 79:2107-2114.
37. Catovsky D., Hamblin T.J., Richards S. UK Medical Research Council CLL3 - A randomized trial of the addition of epirubicin to standard chlorambucil treatment. ASH Annual Meeting Abstracts 2000.
38. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
39. Rai K.R., Peterson B.L., Appelbaum F.R., Tallman M.S., Belch A., Morrison V.A., et al. Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with Chronic Lymphocytic Leukemia (CLL) [abstract]. ASH Annual Meeting Abstracts 2009.
40. Catovsky D., Richards S., Matutes E., Oscier D., Dyer M.J., Bezares R.F., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230-239.
41. Eichhorst B.F., Busch R., Stilgenbauer S., Stauch M., Bergmann M.A., Ritgen M., et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382-3391.
42. Robak T., Blonski J.Z., Kasznicki M., Blasinska-Morawiec M., Krykowski E., Dmoszynska A., et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000, 96:2723-2729.
43. Hillmen P., Skotnicki A.B., Robak T., Jaksic B., Dmoszynska A., Wu J., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
44. Knauf W.U., Lissichkov T., Aldaoud A., Liberati A., Loscertales J., Herbrecht R., et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4378-4384.
45. Knauf W.U., Lissitchkov T., Aldaoud A., Liberati A.M., Loscertales J., Herbrecht R., et al. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia [abstract]. ASH Annual Meeting Abstracts 2010, 116:2449.
46. Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98:2319-2325.
47. Abdelhamid T.H., Al-lahloby N., Kamel A., Elsharkawy N., Zaher A. Fludarabine and cyclophosphamid (Fc) Versus cyclophosphamide, vincristine and prednisone (Cvp) As first line treatment in chronic lymphocytic leukaemia (Cll) [abstract]. Haematologica 2006, 290-291.
48. Ionita H., Chreveresan L., Ionita M., Delamarian M., Racz M. Fludarabine and cyclophosphamide (fc) versus cyclophosphamide, vincristine and prednisone (cvp) as first line therapy in Chronic Lymphocytic Leukemia (CLL) [abstract]. Haematologica 2009, 94:599-600.
49. Eichhorst B.F., Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885-891.
50. Flinn I.W., Neuberg D.S., Grever M.R., Dewald G.W., Bennett J.M., Paietta E.M., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007, 25:793-798.
51. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
52. Robak T., Jamroziak K., Gora-Tybor J., Stella-Holowiecka B., Konopka L., Ceglarek B., et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010, 28:1863-1869.
53. Reynolds C., Di Bella N., Lyons R.M., Hyman W.J., Lee G.L., Richards D.A., et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in b-cell chronic lymphocytic leukemia [abstract]. ASH Annual Meeting Abstracts 2008.
54. Robak T., Blonski J.Z., Gora-Tybor J., Jamroziak K., Dwilewicz-Trojaczek J., Tomaszewska A., et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 2006, 108:473-479.
55. Chan A.W., Hrobjartsson A., Haahr M.T., Gotzsche P.C., Altman D.G. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004, 291:2457-2465.
56. Dickersin K., Min Y.I. Publication bias: the problem that won't go away. Ann N Y Acad Sci 1993, 703:135-146.
57. Song F., Loke Y.K., Walsh T., Glenny A.M., Eastwood A.J., Altman D.G. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009, 338:b1147.
58. Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The National Academies Press; 2011.
59. Conway P.H., Clancy C. Comparative-effectiveness research-implications of the Federal Coordinating Council's report. N Engl J Med 2009, 361:328-330.
60. Volpp K.G., Das A. Comparative effectiveness-thinking beyond medication A versus medication B. N Engl J Med 2009, 361:331-333.